Dianthus Therapeutics (DNTH) Accounts Payables (2017 - 2025)

Dianthus Therapeutics' Accounts Payables history runs 9 years deep, the most recent figure standing at $9.7 million for Q4 2025.

• In Q4 2025, Accounts Payables rose 112.38% year-over-year to $9.7 million; the TTM figure through Dec 2025 stood at $9.7 million (up 112.38% YoY), while the FY2025 annual figure was $9.7 million, up 112.38% from the prior year.
• Accounts Payables was $9.7 million for Q4 2025 at Dianthus Therapeutics, up from $6.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $9.7 million in Q4 2025 to a low of $813000.0 in Q2 2023.
• Historically, Accounts Payables has averaged $3.7 million across 5 years, with a median of $2.8 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables sank 75.66% in 2023, then surged 453.1% in 2024.
• A 5-year view of Accounts Payables shows it stood at $3.0 million in 2021, then tumbled by 61.61% to $1.2 million in 2022, then soared by 123.65% to $2.6 million in 2023, then jumped by 75.44% to $4.6 million in 2024, then surged by 112.38% to $9.7 million in 2025.
• The last three Accounts Payables figures came in at $9.7 million (Q4 2025), $6.7 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.